Key Drivers
- Margin Strength
- Cash Conversion
- Low Leverage
AIAI Summary
GMED should be viewed less as a pure growth story and more as a high-quality compounding story where upside now depends on successful NuVasive/Nevro integration, margin expansion, and sustained cash conversion, while the main risk is that weak technicals and a premium valuation will punish any execution slip or lack of revenue reacceleration.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Strength
- •Cash Conversion
- •Low Leverage
GMED combines strong margins, excellent cash generation, and very low leverage with a premium valuation and notable intangibles/working-capital intensity.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Oversold bounce
- •Reclaim resistance
GMED remains in a damaged short-term downtrend, but deep oversold conditions and stabilization near $75.5-$77 could support a bounce unless it reclaims $85 and then $90-$91. ക ക
Sharp drop through $90-$91 and $85, followed by a brief stabilization near $75.5-$77
Sentiment & News
Key News Insights:
- •EPS beat
- •Revenue surge
- •Guidance raised
GMED posted a strong Q1 2026 beat with faster revenue growth, margin improvement, and a raised outlook, even as the stock remains volatile after a recent pullback.
The results are likely supportive for GMED shares as fundamentals and analyst sentiment improve, though near-term volatility may persist
Similar Companies in Healthcare
Other companies in the same sector with AI ratings